Skip to main content
Addgene

pGL2-Full
(Plasmid #16012)

Full plasmid sequence is not available for this item.

Loading...

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 16012 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pGL2-basic
  • Backbone manufacturer
    Promega
  • Backbone size w/o insert (bp) 5600
  • Vector type
    Mammalian Expression, Luciferase

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    KILLER/DR5
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    3600
  • Entrez Gene
    TNFRSF10B (a.k.a. CD262, DR5, KILLER, KILLER/DR5, TRAIL-R2, TRAILR2, TRICK2, TRICK2A, TRICK2B, TRICKB, ZTNFR9)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site SacI (unknown if destroyed)
  • 3′ cloning site XhoI (unknown if destroyed)
  • 5′ sequencing primer EBVrev
  • 3′ sequencing primer LucNrev
  • (Common Sequencing Primers)

Resource Information

Terms and Licenses

Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

A 3.6 Kb Pst1 fragment from the KILLER/DR5 P1 clone which includes 1.6 Kb upstream of the ATG through Intron 2 in KILLER/DR5 genomic DNA.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pGL2-Full was a gift from Wafik El-Deiry (Addgene plasmid # 16012 ; http://n2t.net/addgene:16012 ; RRID:Addgene_16012)
  • For your References section:

    Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Takimoto R, El-Deiry WS. Oncogene. 2000 Mar 30. 19(14):1735-43. 10.1038/sj.onc.1203489 PubMed 10777207